Introduction

IQVIA, a multinational healthcare data analysis company, has faced a significant fine of $7. 8 million from Italy's Data Protection Authority (GPDP) for failing to properly anonymize health data. This oversight could have put approximately one million patients at risk of data exposure and de-anonymization.

IQVIA fined $7.8 million for failing to properly anonymize health data

Background on IQVIA

IQVIA operates in over 100 countries and handles 68 petabytes of data and 1. 2 billion patient records. The company’s website claims it provides healthcare data analysis, technology, and clinical research services.

Investigation and Findings by GPDP

In April 2025, Italian authorities investigated IQVIA’s data-processing practices. They found that despite the company’s claims of adequate anonymization, its Italian division had created a database containing the health information of roughly one million patients by aggregating data from 800 general practitioners. While IQVIA used a unique code instead of patients' names, the data protection agency discovered that this code could be used to track and de-anonymize patients over time.

The code associated with each patient made it possible to track them over time, and combined with a very detailed set of information (year of birth, sex, diagnoses, symptoms, prescriptions, tests, vaccinations, as well as location data), it made it possible to single out individual patients and, using reasonable means, reidentify them.

Additional Violations by IQVIA

In addition to the fine, Italian authorities ordered IQVIA to bring its practices into compliance within 120 days. The company processed data without an appropriate legal basis and did not inform patients. Furthermore, IQVIA allegedly did not establish or follow any data retention periods, with the GPDP finding records dating back as far as 2001. For a subset of 3,300 patients in IQVIA's database, the company also included names, tax identification numbers, addresses, and contact details.

Company Response

In response to the fine, IQVIA stated that they are committed to the responsible use of data and information and continue to cooperate with the Authority. They maintain robust safeguards, including the use of pseudonymization and encryption, to support responsible data use in healthcare. The company acknowledges the decision adopted by the Italian Data Protection Authority and reserves the right to appeal. The dataset to which the Italian Data Protection Authority's decision relates is not used by IQVIA in the conduct of clinical research services and does not relate to the conduct of clinical trials on behalf of the sponsors.

Conclusion

This fine highlights the importance of proper data anonymization practices and the potential risks of inadequate data handling. Companies like IQVIA must ensure that they comply with data protection regulations to protect patient privacy and avoid significant financial penalties.

Related Articles

Comments